Coronavirus drug combo, baricitinib plus remdesivir, gets FDA emergency approval

coronavirus drug combo baricitinib plus remdesivir gets fda emergency approval

Sumary of Coronavirus drug combo, baricitinib plus remdesivir, gets FDA emergency approval:

  • Food and Drug Administration (FDA) on Thursday issued emergency approval to a drug combo to treat moderate to seriously ill coronavirus patients..
  • The FDA said the drugs cut patients’ time to recovery in a National Institute of Allergy and Infectious Diseases-sponsored trial dubbed the Adaptive COVID-19 Treatment Trial (ACTT-2)..
  • Among 1,033 coronavirus patients in the trial with at least a moderate course of disease, patients on the drug combo saw seven days to recovery, while the other group (placebo plus remdesivir) took eight days..
  • Food and Drug Administration (FDA) on Thursday issued emergency approval to a drug combo to treat moderate to seriously ill, hospitalized coronavirus patients..
  • “The FDA emergency authorization of this combination therapy represents an incremental step forward in the treatment of COVID-19 in hospitalized patients, and FDA first authorization of a drug that acts on the inflammation pathway,”.
  • Meanwhile, Gilead remdesivir had already seen FDA-approval as the first COVID-19 treatment for patients over 12…

Close

Languages